
Wellington Partners appoints Essig as venture partner

Wellington Partners has appointed Stuart Essig as venture partner in its life sciences team.
Prior to joining Wellington, Essig served as a board member on various US life sciences companies. Essig has a background in medical technology and healthcare investment banking. His appointment will strengthen the VC's footprint in the US.
The new venture partner currently serves as chairman of the board of directors of Integra Life Sciences following a 15-year stint as the company's CEO. Prior to Integra, Essig was managing director at Goldman Sachs, supervising the firm's medical technology practice. His board experience includes St Jude Medical Corporation, Breg, Zimmer Holdings and Vital Signs.
Wellington is a pan-European VC firm with offices in Munich, London and Zurich. The firm has more than €800m of assets under management in the life sciences, digital media and resource efficiency sectors. Its latest fund, Wellington Partners IV Life Science, held its first closing in September and is expected to reach €120m.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater